Vanguard Global Advisers
ENTA icon

Vanguard Global Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

Vanguard Global Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Sell
10,549
-12,505
-54% -$168K ﹤0.01% 2608
2026
Q1 		$291K Buy
+23,054
New +$309K ﹤0.01% 2261

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Global Advisers's ENTA Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Enanta Pharmaceuticals (ENTA) stake by 54% in Q2 2026, selling an estimated $168K and leaving 10,549 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #2608.

Vanguard Global Advisers first reported a position in ENTA in Q1 2026 and has held it in 2 quarters since. The position peaked at $291K in Q1 2026. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Vanguard Global Advisers held 10,549 shares of Enanta Pharmaceuticals worth $154K as of Q2 2026.
  • Vanguard Global Advisers sold 12,505 Enanta Pharmaceuticals shares in Q2 2026, an estimated $168K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2608 holding.
  • Vanguard Global Advisers first reported a position in Enanta Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Enanta Pharmaceuticals position peaked at $291K in Q1 2026.
  • 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.